These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 8026028

  • 21. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H.
    Circulation; 1995 Feb 15; 91(4):1175-81. PubMed ID: 7850956
    [Abstract] [Full Text] [Related]

  • 22. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y.
    Arterioscler Thromb; 1993 Apr 15; 13(4):563-70. PubMed ID: 8385480
    [Abstract] [Full Text] [Related]

  • 23. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ, Follenfant MJ, Ford AJ.
    Cardiovasc Res; 1991 Mar 15; 25(3):184-91. PubMed ID: 1903080
    [Abstract] [Full Text] [Related]

  • 24. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Mizuo H, Yuzuriha T, Yui Y, Kawai C.
    J Cardiovasc Pharmacol; 1991 May 15; 17(5):738-46. PubMed ID: 1713988
    [Abstract] [Full Text] [Related]

  • 25. Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
    Van de Werf F, Lijnen HR, Collen D.
    Coron Artery Dis; 1993 Oct 15; 4(10):929-33. PubMed ID: 8269200
    [Abstract] [Full Text] [Related]

  • 26. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
    Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E.
    Circulation; 1997 Jan 21; 95(2):351-6. PubMed ID: 9008448
    [Abstract] [Full Text] [Related]

  • 27. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV, Frank JD, Craft TJ, Sundboom JL, Smith GF.
    J Pharmacol Exp Ther; 1992 Jan 21; 260(1):64-70. PubMed ID: 1731052
    [Abstract] [Full Text] [Related]

  • 28. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U, Dörge L, Fischer S.
    Br J Pharmacol; 1996 May 21; 118(2):271-6. PubMed ID: 8735626
    [Abstract] [Full Text] [Related]

  • 29. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 May 21; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 30. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K.
    J Cardiovasc Pharmacol; 1991 Jul 21; 18(1):111-9. PubMed ID: 1719279
    [Abstract] [Full Text] [Related]

  • 31. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar 21; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
    Cambier P, van de Werf F, Larsen GR, Collen D.
    J Cardiovasc Pharmacol; 1988 Apr 21; 11(4):468-72. PubMed ID: 2453751
    [Abstract] [Full Text] [Related]

  • 34. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
    Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, Kawai C.
    Jpn J Pharmacol; 1993 Nov 21; 63(3):319-25. PubMed ID: 8107325
    [Abstract] [Full Text] [Related]

  • 35. Production of vampire bat plasminogen activator DSPA alpha 1 in CHO and insect cells.
    Petri T, Langer G, Bringmann P, Cashion L, Shallow S, Schleuning WD, Donner P.
    J Biotechnol; 1995 Feb 21; 39(1):75-83. PubMed ID: 7766013
    [Abstract] [Full Text] [Related]

  • 36. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.
    Martin U, Kaufmann B, Neugebauer G.
    Clin Pharmacokinet; 1999 Apr 21; 36(4):265-76. PubMed ID: 10320949
    [Abstract] [Full Text] [Related]

  • 37. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 21; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 38. Vampire bats yield potent clot buster for ischemic stroke.
    Grandjean C, McMullen PC, Newschwander G.
    J Cardiovasc Nurs; 2004 Apr 21; 19(6):417-20. PubMed ID: 15529064
    [Abstract] [Full Text] [Related]

  • 39. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
    Mellott MJ, Holahan MA, Lynch JJ, Vlasuk GP, Dunwiddie CT.
    Circ Res; 1992 Jun 21; 70(6):1152-60. PubMed ID: 1576736
    [Abstract] [Full Text] [Related]

  • 40. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar 21; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.